Summer Sale
50% off Premium Yearly
Opinions Cameron Hurst
Gilead Sciences Inc.GILDCOMMENTDec 22, 2015
Cameron HurstStock price when the opinion was issued
As of Jun 17, 2026. Market Open.
You might be interested:
It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Has long owned this, because it's a value stock and keeps raising its dividend.
Brian Belski
Jim Lebenthal;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Gilead Sciences (GILD-Q) or Celgene (CELG-Q)? From an earnings forecast revision standpoint, this one is going up while Celgene is going down, so if you had to pick between the 2 on an earnings revision basis, you definitely have more tailwind with this one. They both have good pipelines, both good companies. This is highly interest rate sensitive because it is a huge cash flow business and is all discounted cash flow in Pharma and biotech, and you have to be very careful when going into a rising rate cycle with serious cash flow and discounting type structures. He is positive on the company, but is watching very carefully.